<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <billNumber>2543</billNumber>
    <createDate>2019-09-26T04:27:33Z</createDate>
    <updateDate>2021-06-11T22:00:41Z</updateDate>
    <originChamber>Senate</originChamber>
    <billType>S</billType>
    <introducedDate>2019-09-25</introducedDate>
    <congress>116</congress>
    <recordedVotes />
    <committees>
      <billCommittees>
        <item>
          <systemCode>ssfi00</systemCode>
          <name>Finance Committee</name>
          <chamber>Senate</chamber>
          <type>Standing</type>
          <subcommittees />
          <activities>
            <item>
              <name>Reported original measure</name>
              <date>2019-09-25T16:58:27Z</date>
            </item>
          </activities>
        </item>
      </billCommittees>
    </committees>
    <committeeReports>
      <committeeReport>
        <citation>S. Rept. 116-120</citation>
      </committeeReport>
    </committeeReports>
    <relatedBills>
      <item>
        <latestTitle>Star Rating for Biosimilars Act</latestTitle>
        <congress>116</congress>
        <number>4629</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-10-18</actionDate>
          <text>Sponsor introductory remarks on measure. (CR H8232)</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Drug Price Transparency in Medicaid Act of 2019</latestTitle>
        <congress>116</congress>
        <number>5281</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-12-04</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Payment Commission Data Act of 2019</latestTitle>
        <congress>116</congress>
        <number>1264</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-02-15</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Payment Commission Data Act of 2019</latestTitle>
        <congress>116</congress>
        <number>1781</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-10-29</actionDate>
          <text>Received in the Senate and Read twice and referred to the Committee on Finance.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Improving Low-Income Access to Prescription Drugs Act of 2019</latestTitle>
        <congress>116</congress>
        <number>3029</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-06-04</actionDate>
          <text>Subcommittee Hearings Held.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Capping Drug Costs for Seniors Act of 2019</latestTitle>
        <congress>116</congress>
        <number>4649</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2019-10-30</actionDate>
          <text>Sponsor introductory remarks on measure. (CR H8607)</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>A bill to amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate information.</latestTitle>
        <congress>116</congress>
        <number>801</number>
        <type>S</type>
        <latestAction>
          <actionDate>2019-03-14</actionDate>
          <text>Read twice and referred to the Committee on Finance.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Improving Low Income Access to Prescription Drugs Act of 2019</latestTitle>
        <congress>116</congress>
        <number>1999</number>
        <type>S</type>
        <latestAction>
          <actionDate>2019-06-27</actionDate>
          <text>Read twice and referred to the Committee on Finance.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>GENE Therapy Payment Act</latestTitle>
        <congress>116</congress>
        <number>5882</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2020-02-12</actionDate>
          <text>Referred to the House Committee on Energy and Commerce.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Prescription Drug Pricing Reduction Act of 2020</latestTitle>
        <congress>116</congress>
        <number>4199</number>
        <type>S</type>
        <latestAction>
          <actionDate>2020-07-02</actionDate>
          <text>Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228)</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <latestTitle>Medicare Prescription Drug Fraud Prevention Act of 2019</latestTitle>
        <congress>116</congress>
        <number>1505</number>
        <type>S</type>
        <latestAction>
          <actionDate>2019-05-16</actionDate>
          <text>Read twice and referred to the Committee on Finance.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2019-09-25</actionDate>
        <committees />
        <links />
        <sourceSystem>
          <code>0</code>
          <name>Senate</name>
        </sourceSystem>
        <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionDate>2019-09-25</actionDate>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
        <links />
        <sourceSystem>
          <code>0</code>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Finance. Original measure reported to Senate by Senator Grassley. With written report No. 116-120.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2019-09-25</actionDate>
        <links />
        <text>Committee on Finance. Original measure reported to Senate by Senator Grassley. With written report No. 116-120.</text>
        <type>Committee</type>
        <actionCode>14000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>ssfi00</systemCode>
            <name>Finance Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2019-09-25</actionDate>
        <links />
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees />
      </item>
      <actionTypeCounts>
        <placedOnCalendarGeneralOrders>1</placedOnCalendarGeneralOrders>
        <originalBillReported>1</originalBillReported>
        <reportedToSenate>1</reportedToSenate>
        <introducedInSenate>1</introducedInSenate>
      </actionTypeCounts>
      <actionByCounts>
        <senate>4</senate>
      </actionByCounts>
    </actions>
    <sponsors>
      <item>
        <bioguideId>G000386</bioguideId>
        <fullName>Sen. Grassley, Chuck [R-IA]</fullName>
        <firstName>CHARLES</firstName>
        <middleName>ERNEST</middleName>
        <lastName>GRASSLEY</lastName>
        <party>R</party>
        <state>IA</state>
        <identifiers>
          <lisID>457</lisID>
          <bioguideId>G000386</bioguideId>
          <gpoId>8316</gpoId>
        </identifiers>
        <byRequestType />
      </item>
    </sponsors>
    <cosponsors />
    <cboCostEstimates>
      <item>
        <pubDate>2019-09-26T15:47:40Z</pubDate>
        <title>Status of CBO’s cost estimate for S. 2543, the Prescription Drug Pricing Reduction Act of 2019</title>
        <url>https://www.cbo.gov/publication/55663</url>
      </item>
    </cboCostEstimates>
    <laws />
    <notes />
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <billSubjects>
        <legislativeSubjects>
          <item>
            <name>Accounting and auditing</name>
          </item>
          <item>
            <name>Administrative law and regulatory procedures</name>
          </item>
          <item>
            <name>Appropriations</name>
          </item>
          <item>
            <name>Congressional oversight</name>
          </item>
          <item>
            <name>Department of Health and Human Services</name>
          </item>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Drug therapy</name>
          </item>
          <item>
            <name>Fraud offenses and financial crimes</name>
          </item>
          <item>
            <name>Genetics</name>
          </item>
          <item>
            <name>Government information and archives</name>
          </item>
          <item>
            <name>Government studies and investigations</name>
          </item>
          <item>
            <name>Health care costs and insurance</name>
          </item>
          <item>
            <name>Health care coverage and access</name>
          </item>
          <item>
            <name>Health care quality</name>
          </item>
          <item>
            <name>Health technology, devices, supplies</name>
          </item>
          <item>
            <name>Home and outpatient care</name>
          </item>
          <item>
            <name>Hospital care</name>
          </item>
          <item>
            <name>Indian social and development programs</name>
          </item>
          <item>
            <name>Inflation and prices</name>
          </item>
          <item>
            <name>Intergovernmental relations</name>
          </item>
          <item>
            <name>Manufacturing</name>
          </item>
          <item>
            <name>Medicaid</name>
          </item>
          <item>
            <name>Medical ethics</name>
          </item>
          <item>
            <name>Medicare</name>
          </item>
          <item>
            <name>Minority health</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
          <item>
            <name>Public contracts and procurement</name>
          </item>
          <item>
            <name>Public participation and lobbying</name>
          </item>
          <item>
            <name>Retail and wholesale trades</name>
          </item>
          <item>
            <name>Social work, volunteer service, charitable organizations</name>
          </item>
          <item>
            <name>State and local government operations</name>
          </item>
        </legislativeSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
      </billSubjects>
    </subjects>
    <summaries>
      <billSummaries>
        <item>
          <versionCode>00</versionCode>
          <actionDate>2019-09-25</actionDate>
          <actionDesc>Introduced in Senate</actionDesc>
          <lastSummaryUpdateDate>2020-02-20T20:36:48Z</lastSummaryUpdateDate>
          <text><![CDATA[<p><b>Prescription Drug Pricing Reduction Act of 2019</b></p> <p>This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid. </p> <p>Among other things, the bill</p> <ul> <li>requires drug manufacturers to issue rebates to the Centers for Medicare &amp; Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation; </li> <li>requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers;</li> <li>reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit;</li> <li>requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;</li> <li>requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and</li> <li>increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.</li> </ul>]]></text>
          <updateDate>2019-09-25T04:00:00Z</updateDate>
          <name>Introduced in Senate</name>
        </item>
        <item>
          <versionCode>25</versionCode>
          <actionDate>2019-09-25</actionDate>
          <actionDesc>Reported to Senate</actionDesc>
          <lastSummaryUpdateDate>2020-02-24T18:43:04Z</lastSummaryUpdateDate>
          <text><![CDATA[<p><b>Prescription Drug Pricing Reduction Act of 2019</b></p> <p>This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid. </p> <p>Among other things, the bill</p> <ul> <li>requires drug manufacturers to issue rebates to the Centers for Medicare &amp; Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation; </li> <li>requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers;</li> <li>reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit;</li> <li>requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;</li> <li>requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and</li> <li>increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.</li> </ul>]]></text>
          <updateDate>2019-09-25T18:13:36Z</updateDate>
          <name>Reported to Senate</name>
        </item>
      </billSummaries>
    </summaries>
    <title>Prescription Drug Pricing Reduction Act of 2019</title>
    <titles>
      <item>
        <titleType>Short Title(s) as Reported to Senate</titleType>
        <parentTitleType>Short Title</parentTitleType>
        <title>Prescription Drug Pricing Reduction Act of 2019</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <parentTitleType>Short Title</parentTitleType>
        <title>Prescription Drug Pricing Reduction Act of 2019</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <parentTitleType />
        <title>An original bill to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes.</title>
        <chamberCode />
        <chamberName />
      </item>
      <item>
        <titleType>Display Title</titleType>
        <parentTitleType />
        <title>Prescription Drug Pricing Reduction Act of 2019</title>
        <chamberCode />
        <chamberName />
      </item>
    </titles>
    <amendments />
    <textVersions>
      <item>
        <type>Reported to Senate</type>
        <date>2019-09-25T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116s2543rs/xml/BILLS-116s2543rs.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2019-09-25</actionDate>
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.</text>
      <links />
    </latestAction>
    <calendarNumbers>
      <item>
        <calendar>Senate Calendar of Business</calendar>
        <number>0225</number>
      </item>
    </calendarNumbers>
    <version>1.0.0</version>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

